FDA will take into account a reference biologic product’s off-label use in considering whether the totality of the evidence supports approval of a biosimilar, the agency suggested at the first advisory committee review of a 351(k) application.
During the Oncologic Drugs Advisory Committee’s Jan. 7 meeting on Sandoz Inc.’s Zarxio – a proposed biosimilar of Amgen Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?